Maegim한국어

드림씨아이에스

223250KOSDAQSector: Pharma & Biotech
₩2,830▼ 1.57%Market cap ₩69.6BAs of Jul 21, 2026 close · updated once daily
B
Grade B62.9 ptsTop 27% of 2,523 stocks
Financial strength
54.1
Growth momentum
61.1
Price attractiveness
74.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

54.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
88.6%
✗ Below median · Top 71.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
107.6%
✗ Below median · Top 75% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
7.9%
✓ Above median · Top 22.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
9.3%
✓ Above median · Top 14.4% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

61.1
How much did revenue grow in a year?
Revenue growth (YoY)
13.6%
✓ Above median · Top 33.6% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
19.7%
✓ Above median · Top 13.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
3.6%
✗ Below median · Top 50.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-10.0%
✗ Below median · Top 58.3% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

74.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
9.8x
✓ Above median · Top 14% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.91x
✓ Above median · Top 37.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15